

## MicroVention Raises \$19 Million in Late-Stage Financing

*Capital to Fuel Increased Sales and Marketing Initiatives*

ALISO VIEJO, Calif. -- August 27, 2002 -- MicroVention, Inc., a leading developer, manufacturer and marketer of minimally invasive treatments for cerebral vascular diseases, announced today it recently closed a \$19 million round of Series D venture capital funding. Capital raised in this round brings total financing in MicroVention to approximately \$43 million. This funding provides MicroVention with the capital required to continue executing on its sales, marketing and development plans.

U.S. Venture Partners, one of Silicon Valley's leading venture capital firms, led the investment. Also participating were A.G Edwards Capital and previous investors Crosspoint Venture Partners, Advanced Technology Ventures, De Novo Ventures, Delphi Ventures and Asset Management Partners.

"We are pleased such high quality investors have chosen to make a significant investment in MicroVention," said Robert Rosenbluth, President and CEO, MicroVention. "This financing will provide the necessary working capital as we bring the company's leading endovascular devices to market."

The funding will be used to support the further execution of MicroVention's operational plan, including the second quarter 2002 sales launch of the company's MicroPlex Coil System and to accelerate sale and marketing initiatives associated with its HydroCoil Embolic System for the treatment of cerebral aneurysms. The HydroCoil Embolic System recently received 510(k) clearance from the United States Food and Drug Administration (FDA) and CE Mark for the treatment of cerebral aneurysms (see August 15, 2002 release).

"We are very excited about the market potential of the endovascular aneurysm products MicroVention has developed and with the continued fundamental success of the company," said Jonathan Root, M.D., General Partner, U.S. Venture Partners. "We are very impressed with the company's technology, seasoned management team and ability to execute on its overall market strategy."

A cerebral aneurysm is a ballooning of a weakened region of a blood vessel. If left untreated, the aneurysm may continue to weaken until it ruptures and bleeds into the brain. Approximately 2% to 5% of the U.S. Population is estimated to have cerebral aneurysms- most of which go undetected. Each year approximately 150,000 patients worldwide are treated for cerebral aneurysms of which 20% are estimated to be treated by endovascular coil embolization rather than traditional surgical approaches. Industry experts believe up to 75% of patients currently being treated for cerebral aneurysms could be treated with endovascular devices evidencing a near term market potential for such devices of approximately \$500 million. Endovascular embolization is one of the most rapidly growing vascular markets for medical technology. MicroVention sells its products through its direct sales force in the United States, France, Germany and the United Kingdom and through distributors in various other countries.

### **About MicroVention, Inc.**

Microvention, Inc. ([www.microvent.com](http://www.microvent.com)) is a privately-held medical device company dedicated to the development and commercialization of new catheter-based technologies for the endovascular treatment of peripheral and cerebral vascular diseases. The company has received 510(k) clearance and CE Mark for both its MicroPlex Coil System and the HydroCoil Embolization System, its next generation endovascular coil system designed to treat cerebral aneurysms.

### **About U.S. Venture Partners**

U.S. Venture Partners (USVP) ([www.usvp.com](http://www.usvp.com)) is a leading Silicon Valley-based venture capital firm dedicated to helping entrepreneurs build world-class companies that are leaders in their industry. USVP focuses on early stage opportunities in sectors where the Partners have the domain expertise, operating experience and network of relationships to provide meaningful contribution to the success of the enterprise. These sectors include digital communications and networking systems, Internet and eCommerce infrastructure, semiconductors and optical components, enterprise and technical software, and medical devices and biopharmaceuticals. Since its inception in 1981, USVP has raised more than \$2.5 billion in eight funds, including a \$1 billion fund that closed in January 2001, and has invested over \$1.1 billion in more than 271 companies. USVP partners have been the lead investors in such notable life science industry leaders as Amgen, where USVP founding partner Bill Bowes was the founding seed investor, Advanced Cardiovascular Systems, Applied Biosystems, CardioThoracic Systems, Nellcor, Cell Genesys and Vical.

### **About A.G Edwards Capital**

A.G. Edwards Capital ([www.agedwards.com](http://www.agedwards.com)) is a private equity firm affiliated with St. Louis-based brokerage firm A.G Edwards & Sons, Inc. A.G Edwards Capital manages approximately \$230 million for its Limited Partners, made up of high net worth individuals and institutions.

### **MicroVention Contacts:**

Robert Rosenbluth, President, CEO  
William Hughes, Vice President, CFO  
Ph. 949-768-1184  
Fx. 949-768-0464